25947-14-2

Usage

Chemical Class

Phthalazines, organic compounds containing a phthalazine moiety.

Structure

1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester.

Activity

Potent inhibitor of hypoxia-inducible factor-1 (HIF-1) activation, a key regulator of tumor adaptation to microenvironmental stress.

抗癌能力

Displays potential anticancer activity through its ability to inhibit angiogenesis and reduce tumor growth.

抗炎能力

Possesses anti-inflammatory properties, making it a potential candidate for the development of therapeutic agents for cancer and inflammatory diseases.

Upstream product

• 85-44-9 phthalic anhydride 
• 4743-57-1 phthalidyliden-acetic acid 
• 67-56-1 methanol 
• 25947-11-9 1,2-Dihydro-1-oxophthalazin-4-ylacetic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 138129-02-9 {3-[3-(4-Bromo-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid methyl ester 
• 131337-26-3 {3-[3-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid methyl ester 
• 1316307-92-2 methyl 2-(3-((3-(4-bromo-3-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-94-4 methyl 2-(3-((3-(1-benzylpiperidin-4-yl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-95-5 methyl 2-(3-((3-(2-hydroxyphenyl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-85-3 methyl 3-methoxy-2-(4-oxo-3-((3-phenyl-4,5-dihydroisoxazol-5-yl)methyl)-3,4-dihydrophthalazin-1-yl)acrylate 
• 1316307-86-4 methyl 2-(3-((3-(4-chlorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-87-5 methyl 2-(3-((3-(4-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-88-6 methyl 3-methoxy-2-(3-((3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acrylate 
• 1316307-89-7 methyl 2-(3-((3-(3,4-dimethoxyphenyl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydro phthalazin-1-yl)-3-methoxyacrylate 
• 1316307-90-0 methyl 2-(3-((3-(3-(4-fluorophenoxy)phenyl)-4,5-dihydro isoxazol-5-yl)methyl)-4-oxo-3,4-dihydro-phthalazin-1-yl)-3-methoxyacrylate 
• 1334951-48-2 2-((3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-((5-(methylthio)-1,3,4-oxadiazol-2-yl)methyl)phthalazin-1(2H)-one 
• 1334951-49-3 2-((3-(3,4-dimethoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-((5-(methylthio)-1,3,4-oxadiazol-2-yl)methyl)phthalazin-1(2H)-one 
• 1334951-52-8 2-((3-(2-hydroxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-((5-(methylthio)-1,3,4-oxadiazol-2-yl)methyl)phthalazin-1(2H)-one 

Relevant academic research and scientific papers

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Current treatments only slow down disease progression, making new therapeutic strategies compelling. Increasing evidence suggests that S1P2 antagonists could be effective agents against fibrotic diseases. Our compound collection was mined for molecules possessing substructure features associated with S1P2 activity. The weakly potent indole hit 6 evolved into a potent phthalazone series, bearing a carboxylic acid, with the aid of a homology model. Suboptimal pharmacokinetics of a benzimidazole subseries were improved by modifications targeting potential interactions with transporters, based on concepts deriving from the extended clearance classification system (ECCS). Scaffold hopping, as a part of a chemical enablement strategy, permitted the rapid exploration of the position adjacent to the carboxylic acid. Compound 38, with good pharmacokinetics and in vitro potency, was efficacious at 10 mg/kg BID in three different in vivo mouse models of fibrotic diseases in a therapeutic setting.

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS

The present invention discloses compounds according to Formula (I) Wherein R1, R2, L, A1, A2, A3, Cy and the subscript n are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.

Synthesis, antimicrobial and cytotoxicity studies of some novel modified strobilurin derivatives

A series of some new 3-isoxazoline substituted methyl-3-methoxy-2-(4-oxo-3, 4-dihydrophthalazin-1-yl)prop-2-enoate derivatives were designed and synthesized from methyl-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate, which in turn was prepared from phthalic anhydride. The structures of synthesized new compounds were characterized by spectral data and studied for their antimicrobial activities and cytotoxicity. Several of these compounds showed good antimicrobial activity.

Synthesis and antimicrobial activity of 2-substituted [4-(1,3,4-oxadiazol- 2-yl methyl)] phthalazin-1(2H)-one derivatives

A series of new 2-substituted [4-(1,3,4-oxadiazol-2-yl)methyl]phthalazin- 1(2H)-one derivatives 7a-h to 9a-h were designed and synthesized from methyl (4-oxo-3,4-dihydrophthalazin-1-yl)acetate (4), which in was turn prepared from phthalic anhydride. The structure of synthesized new compounds were characterized by spectral data and screened for their antimicrobial activities against various bacteria and fungi strains. Several of these compounds showed antimicrobial activity.